  Mycobacterium tuberculosis infection can involve all immune system components
and can result in different disease outcomes. The antibiotic TB drugs require
strict adherence to prevent both disease relapse and mutation of drug- and
multidrug-resistant strains. To overcome the constraints of pathogen-directed
therapy, host-directed therapy has attracted more attention in recent years as
an adjunct therapy to enhance host immunity to fight against this intractable
pathogen. The goal of this paper is to investigate in-host tuberculosis models
to provide insights into therapy development. Focusing on therapy-targeting
parameters, the parameter regions for different disease outcomes are identified
from an established ODE model. Interestingly, the ODE model also demonstrates
that the immune responses can both benefit and impede disease progression,
depending on the number of bacteria engulfed and released by macrophages. We
then develop two It\^{o} SDE models, which consider the impact of demographic
variations at the cellular level and environmental variations during therapies
along with demographic variations. The SDE model with demographic variation
suggests that stochastic fluctuations at the cellular level have significant
influences on (1) the T-cell population in all parameter regions, (2) the
bacterial population when parameters located in the region with multiple
disease outcomes, and (3) the uninfected macrophage population in the parameter
region representing active disease. Further, considering environmental
variations from therapies, the second SDE model suggests that disease
progression can slow down if therapies (1) can have fast return rates and (2)
can bring parameter values into the disease clearance regions.
